增持前，李西廷未直接持有公司股份，通过Smartco Development Limited间接控制公司股份327,072,335股，占公司股份的26.98%；其一致行动人徐航通过 Magnifice (HK) Limited间接控制公司股份296,951,000股，占公司股份的24.49%，即增持前李西廷及其一致行动人合计控制公司624,023,335股，占公司股份的 51.47%。增持后，李西廷直接持有公司股份1,005,381股，Smartco Development和Magnifice (HK)持有公司股份情况未变，李西廷及其一致行动人合计控制公 司股份625,028,716股，占公司股份的51.55%。 公告显示，2025年11月27日，深圳迈瑞生物医疗电子股份有限公司披露计划增持公告，公司实际控制人之一、董事长李西廷，基于对公司内在价值认可和未 来持续发展信心，践行促进资本市场高质量发展社会责任，计划自2025年11月27日起6个月内，通过集中竞价交易方式增持公司股份，拟增持金额为2亿元 （含交易费用）。 2025年12月12日，李西廷提前完成本次增持计划。2025年11月27日至2025年12月 ...

（编辑 任世碧） 证券日报网讯 12月18日，迈瑞医疗在互动平台回答投资者提问时表示，2025年前三季度，公司营收达 258.34亿元，净利润75.70亿元。前三季度国际业务占公司整体收入的比重已经超过了一半，随着持续深 入的本地化平台建设，未来几年国际收入占整体收入的比重将不断提升，尤其发展中国家将维持快速增 长的趋势，并且伴随收入结构中高端客户占比持续提升，国际业务的盈利水平有望稳步提升。通过提高 试剂核心原料自制率、提升高毛利业务和高端客户收入占比，以及发展中国家持续高增长，公司有能力 在一个竞争激烈的环境中维持较高的盈利水平，同时确保各业务线的市场份额进一步扩大。 ...

证券日报网讯12月18日，迈瑞医疗（300760）在互动平台回答投资者提问时表示，截至2025年9月30 日，公司股东总数为108835户。 ...

Group 1 - The core viewpoint of the article highlights that despite a significant drop in the stock price of Mindray Medical, its actual controller, Li Xiting, has recently increased his stake by approximately 200 million yuan, which is relatively minor compared to previous large-scale reductions [1] - Since the beginning of 2023, Li Xiting and his holding platforms have significantly reduced their stakes, cashing out around 2.5 billion yuan in a single quarter, totaling over 10 billion yuan [1] - Industry insiders believe that the domestic medical and consumables procurement continues to face challenges, and the fundamental aspects of the industry have not yet bottomed out, while overseas operations are facing tariff-related risks [1] Group 2 - As of June 2023, the four holding platforms still collectively held 50 million shares of Mindray Medical, but by June 2025, they are expected to disappear from the list of the top ten shareholders [2] - The estimated cash-out amount from these reductions over the two-year period could exceed 10 billion yuan based on average stock prices [2]

对于迈瑞医疗未来经营和业绩，业内人士认为，国内医疗、耗材集采持续，行业基本面并未见底，而 海外主要业务地区面临关税相关风险。也有分析人士判断，经过四年调整，该公司无论是股价，还是 基本面都有可能迎来反转。 半月增持占总股本不到千分之一 本文字数：1612，阅读时长大约3分钟 作者 | 第一财经 李隽 股价跌破200元大关，相比近500元的历史高点，迈瑞医疗（300760.SZ）的股价，目前已经"膝盖 斩"。 面对股价持续下挫，迈瑞医疗实际控制人李西廷，从11月底开始，在两周多时间内出手增持了约2亿 元的股份。 增持金额虽然不小，但相较于此前减持却显得颇为微弱。2023年以来，李西廷等人控制的持股平台 就大举减持，曾经一个季度就套现大约25亿元，合计已经减持套现过百亿元。 2025.12. 18 根据迈瑞医疗公告，11月27日至12月12日，李西廷使用资金2亿元，累计增持该公司100.5万股，占 公司总股本0.08%的股份，。由于增持已经完成，原定六个月的增持期提前结束。 增持完成后，李西廷其与一致行动人Smartco Development、Magnifice(HK)等，合计持有迈瑞医 疗6.25亿股，占比5 ...

增持完成后，李西廷其与一致行动人Smartco Development、Magnifice(HK)等，合计持有迈瑞医疗6.25亿股，占比51.55%。 半个月已经买完，增持不到总股本千分之一。 股价跌破200元大关，相比近500元的历史高点，迈瑞医疗（300760.SZ）的股价，目前已经"膝盖斩"。 面对股价持续下挫，迈瑞医疗实际控制人李西廷，从11月底开始，在两周多时间内出手增持了约2亿元的股份。 增持金额虽然不小，但相较于此前减持却显得颇为微弱。2023年以来，李西廷等人控制的持股平台就大举减持，曾经一个季度就套现大约25亿元，合计已经 减持套现过百亿元。 对于迈瑞医疗未来经营和业绩，业内人士认为，国内医疗、耗材集采持续，行业基本面并未见底，而海外主要业务地区面临关税相关风险。也有分析人士判 断，经过四年调整，该公司无论是股价，还是基本面都有可能迎来反转。 根据迈瑞医疗公告，11月27日至12月12日，李西廷使用资金2亿元，累计增持该公司100.5万股，占公司总股本0.08%的股份，。由于增持已经完成，原定六 个月的增持期提前结束。 相较于早前减持，李西廷此次增持力度显得有些薄弱。过去三年，李西廷等人的持 ...

Core Insights - The global life support medical device market is projected to reach $75.1 billion in 2024 and is expected to exceed $80 billion in 2025, with a potential to surpass $100 billion in the next five years [3][5] - The domestic life support medical device market in China is rapidly growing, with an estimated market size of 55.7 billion yuan in 2024, expected to reach 61.95 billion yuan in 2025, and potentially reaching 93.2 billion yuan in the next five years [5] Industry Definition and Classification - Life support medical devices are critical equipment used to replace or assist the function of vital organs in emergency situations, primarily utilized in ICUs, emergency rooms, operating rooms, and pre-hospital care [2][3] - Key categories of life support medical devices include blood purification equipment, monitors, ventilators, anesthesia machines, ECG machines, defibrillators, and CPR devices [2][3] Current Industry Development - The life support medical device sector is characterized by high-risk equipment that plays a crucial role in medical rescue and care [3] - The industry has seen rapid market expansion, with significant growth expected in the coming years [3][5] Industry Chain - The upstream of the life support medical device industry includes raw materials, electronic components, biological materials, high-performance batteries, precision sensors, packaging materials, and software systems [5] - The midstream focuses on the research and manufacturing of life support medical devices, while the downstream includes medical institutions, home users, and rehabilitation centers [5] Competitive Landscape - The life support medical device market is marked by high technical barriers and growth potential, with leading domestic companies including Mindray, Yuyue Medical, and Weigao [7] - The market is relatively concentrated, with foreign companies dominating the high-end segment while domestic brands are making breakthroughs in the mid-to-low end and advancing towards high-end products [7] Development Trends - The life support medical device industry is increasingly recognized as essential in modern medicine, with a focus on integrated, precise, and intelligent technologies [10] - The demand for life support medical devices is expected to grow due to the aging population and the rising need for critical care related to severe and emergency patients [10]

医疗设备行业11月更新： 招采金额环比延续增长态势 长江证券研究所医药研究小组 2025-12-17 %% %% %% %% research.95579.com 1 分析师 彭英骐 分析师 徐晓欣 SAC执业证书编号：S0490524030005 SAC执业证书编号：S0490522120001 SFC执业证书编号：BUZ392 分析师及联系人 证券研究报告 • 证券研究报告 • 评级 看好 维持 2 01 设备招采：持续恢复，看好业绩释放 02 集采：县域市场集采占比较低，降幅缓和 03 风险提示 目 录 %% research.95579.com 3 01 设备招采：持续恢复，看好业绩释放 医疗设备行业月度数据跟踪 %% %% %% %% research.95579.com 医疗设备行业历经2023-2024年连续两年下滑后，于2025年迎来拐点，行业回归正增长，主要是由于设备更新政策带动的 医院设备采购的需求增加，未来行业有望回归稳健增长。 %% %% %% %% research.95579.com 4 2025年医疗设备招采恢复正增长 图1：2019-2025H1设备招采总金额情况 图2：201 ...

Group 1 - The "2025 Hurun Global High-Quality Enterprises TOP 1000" list was released, highlighting global economic trends, with the US leading with 410 companies, followed by China with 158, and Japan with 63 [2] - Nvidia surpassed Microsoft and Apple to become the world's most valuable company, valued at 3.28 trillion RMB, while Apple remains second at 2.86 trillion RMB [2] - Walmart is noted as the highest revenue-generating company on the list, with an annual income of 4.8 trillion RMB, while Alphabet holds the title for the highest profit at 790 billion RMB [2] Group 2 - Shenzhen ranks 11th globally with 15 companies on the list, an increase of 3 from the previous year, with 5 companies located in the Futian District [3] - The Greater Bay Area has 38 companies listed, accounting for 24% of China's total, indicating significant regional economic strength [3] - Notably, 8 non-Chinese companies have established their China headquarters in Shenzhen, ranking fourth among Chinese cities [3] Group 3 - The list reflects the concentration of wealth driven by artificial intelligence, with 11 companies valued at over 1 trillion USD, up from 4 five years ago [4] - The top 10 companies have doubled in value to 18.4 trillion RMB, nearing the total market capitalization of A-shares and H-shares combined [4] - Companies like TSMC and Tencent showed remarkable performance, with TSMC increasing by 410 billion RMB and Tencent by 200 billion RMB [4] Group 4 - Companies experiencing significant value declines include Meituan (down 200 billion RMB) and Shein (down 100 billion RMB), along with others like GF Securities, Mindray Medical, Wanhua Chemical, and Sinopec [5]

Core Insights - The "2025 China Sci-Tech Enterprises Innovation Power TOP 500 Development Report" and the corresponding list were released at the "2025 Sci-Tech Enterprises High-Quality Development Conference" by the China Enterprise Evaluation Association [1] Group 1: Rankings and Scores - Huawei Technologies Co., Ltd. ranked first with a score of 954.85, followed by ZTE Corporation at 81'056, Tencent Technology (Shenzhen) Co., Ltd. at 947.12, and Mindray Bio-Medical Electronics Co., Ltd. at 944.51 [2][3] - The top five companies include four from Shenzhen: Huawei, ZTE, Tencent, and Mindray, with Baidu Online Network Technology (Beijing) Co., Ltd. rounding out the top five [2][3] Group 2: Regional Representation - Shenzhen has 54 companies on the list, second only to Beijing, which has 60 [2][11] - The leading sectors for Shenzhen's listed companies include new generation information technology (21 companies), biopharmaceuticals (10 companies), and high-end equipment manufacturing (7 companies) [11] Group 3: Innovation Cluster - The innovation cluster in Shenzhen is characterized by a focus on electronic information as the main body, with a diverse range of industries collaborating [11]